The Role of Prostaglandins in the Progression of Diabetic Retinopathy and the Therapeutic Efficacy of Topical Ketorolac (Acuvail)

Trial Profile

The Role of Prostaglandins in the Progression of Diabetic Retinopathy and the Therapeutic Efficacy of Topical Ketorolac (Acuvail)

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Ketorolac (Primary)
  • Indications Diabetic retinopathy; Retinal disorders
  • Focus Pharmacodynamics
  • Most Recent Events

    • 20 Feb 2017 Status changed from recruiting to withdrawn prior to enrolment.
    • 08 Dec 2015 Planned End Date changed from 1 Jan 2016 to 1 Dec 2016, as reported by ClinicalTrials.gov.
    • 07 Jan 2014 Planned End Date changed from 1 Mar 2013 to 1 Jan 2016 as reported by clinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top